Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women

Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part...

Full description

Saved in:
Bibliographic Details
Published inBMC women's health Vol. 23; no. 1; pp. 68 - 15
Main Authors Yousuf, Syed Douhath, Ganie, Mohammad Ashraf, Urwat, Uneeb, Andrabi, Syed Mudasir, Zargar, Mohammad Afzal, Dar, Mashooq Ahmad, Manzoor-ul-Rehman, Mir, Mudassar, Syed, Rashid, Fouzia
Format Journal Article
LanguageEnglish
Published England BioMed Central 15.02.2023
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored. The relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software. Six months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002). OCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities.
AbstractList Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored.BACKGROUNDPolycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored.The relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software.METHODThe relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software.Six months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002).RESULTSix months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002).OCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities.CONCLUSIONOCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities.
Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored. The relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software. Six months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002). OCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities.
Abstract Background Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored. Method The relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software. Result Six months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002). Conclusion OCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities.
ArticleNumber 68
Author Yousuf, Syed Douhath
Dar, Mashooq Ahmad
Urwat, Uneeb
Andrabi, Syed Mudasir
Ganie, Mohammad Ashraf
Mudassar, Syed
Rashid, Fouzia
Zargar, Mohammad Afzal
Manzoor-ul-Rehman, Mir
Author_xml – sequence: 1
  givenname: Syed Douhath
  surname: Yousuf
  fullname: Yousuf, Syed Douhath
– sequence: 2
  givenname: Mohammad Ashraf
  surname: Ganie
  fullname: Ganie, Mohammad Ashraf
– sequence: 3
  givenname: Uneeb
  surname: Urwat
  fullname: Urwat, Uneeb
– sequence: 4
  givenname: Syed Mudasir
  surname: Andrabi
  fullname: Andrabi, Syed Mudasir
– sequence: 5
  givenname: Mohammad Afzal
  surname: Zargar
  fullname: Zargar, Mohammad Afzal
– sequence: 6
  givenname: Mashooq Ahmad
  surname: Dar
  fullname: Dar, Mashooq Ahmad
– sequence: 7
  givenname: Mir
  surname: Manzoor-ul-Rehman
  fullname: Manzoor-ul-Rehman, Mir
– sequence: 8
  givenname: Syed
  surname: Mudassar
  fullname: Mudassar, Syed
– sequence: 9
  givenname: Fouzia
  surname: Rashid
  fullname: Rashid, Fouzia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36793022$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1uEzEQxxdURD_gBTggH1OJBdv7fUGqIgqVWlKJcrYm3tnEldfe2t5AHosX4ZnwJi1qOXCwbHn-8_N45n-cHBhrMEneMPqesbr84BlvaJFSnsXF6iotnidHLK94WtZVfvDofJgce39LKavqonqZHGZl1WSU86NnzcKBJtKa4EDiENQGyaC0JrPF_PqUBIcQejSBgA7oPAlrJCs0SPDn4NB7ZQ2xHVEmRiVqPWpwBNo17iK91ShHjSkjs4v52VXKTt-RMPbWEYPSWa886UAG69Lfv8js5ut53KOkt8bKbUAi19hbCFNxAWIVg7MBlZl4V_PriCNgWjJo8L0yNhZGolBtIBJjTWu1VBM7qq_PLia1MmSweiu3PihJ7AbclvitaZ3tMYrmi2-n5Ec8m9iSfgCHLQmWtG5cpQam3kySveJV8qID7fH1_X6SfD__dDP_kl4uPse_XqYyL-uQStq1kheQdbwuOQcpl0ihQd5C01HaMQYs53WXsaWsyryEpiwRCsjbJZtmlJ0kF3tua-FWDE71sWhhQYndhXUrAS7-RqMAWlGaFxV0Bc2XTVfHiUuZ50UHGa_bNrI-7lnDuOyxlTiNXT-BPo0YtRYruxFNk0VCGQGze4CzdyP6IHrlp7mDQTt6wauqymmRFU2Uvn381t9HHrwXBfVeMBnBO-yEVAGC2nlRacGomGwu9jYXsRViZ3NRxFT-T-oD_T9JfwASBATJ
CitedBy_id crossref_primary_10_3390_healthcare12111108
crossref_primary_10_3923_ijbc_2024_01_10
crossref_primary_10_3389_fendo_2023_1273542
crossref_primary_10_3390_biomedicines13030709
crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107753
crossref_primary_10_23736_S1593_232X_23_00578_7
crossref_primary_10_1007_s43032_024_01720_7
crossref_primary_10_3389_fendo_2024_1435698
crossref_primary_10_1080_14656566_2024_2371977
Cites_doi 10.1097/MOH.0000000000000389
10.1016/j.fertnstert.2003.10.004
10.1097/01.GME.0000153888.94399.AF
10.1016/S0378-5122(02)00157-3
10.1016/j.fertnstert.2008.09.034
10.1016/j.dsx.2019.05.003
10.2169/internalmedicine.48.2177
10.1177/1076029617727857
10.2174/1389450120666190927122553
10.1080/09513590.2017.1395841
10.1093/humrep/17.7.1729
10.1038/s41598-019-46644-4
10.1084/jem.193.2.263
10.1016/j.cca.2019.09.010
10.1007/BF02786454
10.1159/000334175
10.1055/a-0992-9114
10.1530/EJE-08-0725
10.3389/fendo.2019.00879
10.1155/2018/9591509
10.1016/j.jpag.2016.06.010
10.1038/nprot.2008.73
10.1152/physrev.2001.81.4.1535
10.1016/j.ejogrb.2011.03.015
10.1371/journal.pone.0164021
10.2144/05391RV01
10.1056/NEJMcp033487
10.1038/nrendo.2009.62
10.1007/s12291-020-00901-w
10.1111/j.1538-7836.2005.01690.x
10.1016/j.cyto.2012.06.018
10.1093/qjmed/94.1.31
10.1016/j.metabol.2017.05.001
10.1016/j.fertnstert.2010.08.030
10.1530/JOE-13-0277
10.1210/jcem-21-11-1440
10.1242/jcs.00247
10.1016/j.mimet.2018.02.011
10.1093/humrep/15.4.785
10.1093/humrep/der096
10.1038/s41598-021-84586-y
10.3389/fendo.2019.00699
10.1161/CIRCRESAHA.117.306666
10.1507/endocrj.53.157
10.1016/j.thromres.2019.11.019
10.4103/jhrs.JHRS_95_18
10.1016/0092-8674(93)90367-Y
10.1016/S1043-2760(00)00272-1
10.2337/db08-0127
10.1038/srep17714
10.1016/j.ejogrb.2019.06.018
10.1016/j.dsx.2019.04.032
10.1186/s13048-019-0566-5
10.1080/13813455.2016.1190760
10.2174/1389450120666190715102510
10.1002/ijgo.13125
10.1210/jcem.85.7.6661
10.1093/humrep/dep459
10.1038/sj.ijo.0802502
10.1016/j.snb.2018.03.053
10.1007/BF00280883
10.1093/humrep/del407
ContentType Journal Article
Copyright 2023. The Author(s).
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s12905-023-02187-5
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 1472-6874
EndPage 15
ExternalDocumentID oai_doaj_org_article_a0700457af504b9f8001cc445fa328dd
PMC9933286
36793022
10_1186_s12905_023_02187_5
Genre Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GrantInformation_xml – fundername: DST ,New Delhi, Women scientist scheme
  grantid: SR/WOS-A/LS-642/2012(G).
– fundername: ;
  grantid: SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).
GroupedDBID ---
04C
0R~
23N
2WC
53G
5VS
6J9
6PF
7R6
7RV
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACHQT
ACIHN
ACUHS
ADBBV
ADOJX
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BKEYQ
BMC
BMSDO
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
DU5
E3Z
EBD
EBLON
EBS
ECF
ECT
EIHBH
ESX
EX3
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
ICW
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PMKZF
PQQKQ
PROAC
PSQYO
PSYQQ
QXPDG
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~8M
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
7X8
PPXIY
5PM
PJZUB
PUEGO
ID FETCH-LOGICAL-c468t-c0fdc25a3f28622accbe0a9e2da9f00f11a1428f31bc7646a966ea5a4db193023
IEDL.DBID M48
ISSN 1472-6874
IngestDate Wed Aug 27 01:26:35 EDT 2025
Thu Aug 21 18:38:16 EDT 2025
Fri Jul 11 14:14:21 EDT 2025
Thu Jan 02 22:53:46 EST 2025
Tue Jul 01 00:26:25 EDT 2025
Thu Apr 24 22:59:02 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Monocyte chemoattractant protein-1
Polycystic ovary syndrome
Coagulation
Insulin resistance
Inflammation
Plasminogen activator inhabitor-1
Tumor necrosis factor-α
Oral contraceptive pill
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c468t-c0fdc25a3f28622accbe0a9e2da9f00f11a1428f31bc7646a966ea5a4db193023
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12905-023-02187-5
PMID 36793022
PQID 2777405359
PQPubID 23479
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_a0700457af504b9f8001cc445fa328dd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9933286
proquest_miscellaneous_2777405359
pubmed_primary_36793022
crossref_citationtrail_10_1186_s12905_023_02187_5
crossref_primary_10_1186_s12905_023_02187_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-02-15
PublicationDateYYYYMMDD 2023-02-15
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-15
  day: 15
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC women's health
PublicationTitleAlternate BMC Womens Health
PublicationYear 2023
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References S Nader (2187_CR44) 2007; 22
HJ Teede (2187_CR62) 2010; 93
J Panee (2187_CR67) 2012; 60
BK Tan (2187_CR58) 2008; 57
TD Schmittgen (2187_CR32) 2008; 3
MJ Chen (2187_CR54) 2010; 25
KM Seow (2187_CR56) 2012; 73
M Küçük (2187_CR61) 2011; 38
MA Ganie (2187_CR2) 2020; 149
F Cirillo (2187_CR4) 2019; 10
Q Fatima (2187_CR38) 2019; 13
N Koca (2187_CR68) 2021; 46
G Amato (2187_CR13) 2003; 101
2187_CR26
VL Armstrong (2187_CR45) 2001; 94
DS Milstone (2187_CR12) 2015; 117
B Xing (2187_CR28) 2018; 265
O Bilgir (2187_CR53) 2009; 48
DI Koleva (2187_CR7) 2016; 122
D Ferriman (2187_CR27) 1961; 21
W Hu (2187_CR36) 2011; 157
P Dulicek (2187_CR20) 2018; 24
M Kishimoto (2187_CR49) 2006; 53
R Deswal (2187_CR1) 2020; 13
M Luque-Ramírez (2187_CR55) 2009; 160
V Bianconi (2187_CR15) 2018; 25
LR Languino (2187_CR10) 1993; 73
K Gariani (2187_CR18) 2020; 185
M van Rooijen (2187_CR51) 2006; 4
SD Yousuf (2187_CR23) 2018; 148
T Urano (2187_CR16) 2019; 20
2187_CR33
S Nilsson (2187_CR47) 2001; 81
T Shah (2187_CR40) 2022
GS Hotamisligil (2187_CR64) 2003; 27
M Robinson-Rechavi (2187_CR48) 2003; 116
SF de Medeiros (2187_CR60) 2018; 2018
DB Petitti (2187_CR35) 2006; 4
BK Tan (2187_CR59) 2013; 219
SD Yousuf (2187_CR22) 2017; 30
MA Ganie (2187_CR39) 2019; 10
L Kong (2187_CR11) 2020; 21
Y Kawazoe (2187_CR66) 2001; 193
E Villa-Rodríguez (2187_CR34) 2018; 147
M Amiri (2187_CR21) 2017; 73
S Manzoor (2187_CR24) 2019; 9
A Lindholm (2187_CR57) 2011; 26
B Fève (2187_CR63) 2009; 5
H Tatsumi (2187_CR50) 2002; 42
DE Moller (2187_CR65) 2000; 11
E Hatziagelaki (2187_CR8) 2020; 128
K Elter (2187_CR43) 2002; 17
J-l Zhu (2187_CR42) 2019; 499
SUA Rasool (2187_CR3) 2019; 13
ASM Moin (2187_CR69) 2021; 11
P Jin (2187_CR19) 2018; 34
D Cibula (2187_CR46) 2000; 15
L Gao (2187_CR14) 2016; 11
NM Rashad (2187_CR6) 2019; 12
Q Sun (2187_CR5) 2019; 240
M Hemelaar (2187_CR52) 2005; 12
JS Hayflick (2187_CR9) 1998; 17
A Katz (2187_CR29) 2000; 85
ML Wong (2187_CR31) 2005; 39
WD James (2187_CR41) 2005; 352
DR Matthews (2187_CR30) 1985; 28
J Yarmolinsky (2187_CR17) 2016; 6
CS Atabekoglu (2187_CR37) 2011; 95
S Manzoor (2187_CR25) 2021; 36
References_xml – volume: 101
  start-page: 1177
  issue: 6
  year: 2003
  ident: 2187_CR13
  publication-title: Obstet Gynecol
– volume: 25
  start-page: 44
  issue: 1
  year: 2018
  ident: 2187_CR15
  publication-title: Curr Opin Hematol
  doi: 10.1097/MOH.0000000000000389
– ident: 2187_CR26
  doi: 10.1016/j.fertnstert.2003.10.004
– volume: 12
  start-page: 526
  issue: 5
  year: 2005
  ident: 2187_CR52
  publication-title: Menopause
  doi: 10.1097/01.GME.0000153888.94399.AF
– volume: 42
  start-page: 287
  issue: 4
  year: 2002
  ident: 2187_CR50
  publication-title: Maturitas
  doi: 10.1016/S0378-5122(02)00157-3
– volume: 93
  start-page: 184
  issue: 1
  year: 2010
  ident: 2187_CR62
  publication-title: Fertil Steril
  doi: 10.1016/j.fertnstert.2008.09.034
– volume: 13
  start-page: 2098
  issue: 3
  year: 2019
  ident: 2187_CR3
  publication-title: Diabetes Metab Syndr
  doi: 10.1016/j.dsx.2019.05.003
– volume: 48
  start-page: 1193
  issue: 14
  year: 2009
  ident: 2187_CR53
  publication-title: Intern Med
  doi: 10.2169/internalmedicine.48.2177
– volume: 24
  start-page: 797
  issue: 5
  year: 2018
  ident: 2187_CR20
  publication-title: Clin Appl Thromb Hemost
  doi: 10.1177/1076029617727857
– volume: 21
  start-page: 328
  issue: 4
  year: 2020
  ident: 2187_CR11
  publication-title: Curr Drug Targets
  doi: 10.2174/1389450120666190927122553
– volume: 34
  start-page: 272
  issue: 4
  year: 2018
  ident: 2187_CR19
  publication-title: Gynecol Endocrinol
  doi: 10.1080/09513590.2017.1395841
– volume: 17
  start-page: 1729
  issue: 7
  year: 2002
  ident: 2187_CR43
  publication-title: Hum Reprod
  doi: 10.1093/humrep/17.7.1729
– volume: 9
  start-page: 10182
  issue: 1
  year: 2019
  ident: 2187_CR24
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-46644-4
– volume: 193
  start-page: 263
  issue: 2
  year: 2001
  ident: 2187_CR66
  publication-title: J Exp Med
  doi: 10.1084/jem.193.2.263
– volume: 499
  start-page: 142
  year: 2019
  ident: 2187_CR42
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2019.09.010
– volume: 17
  start-page: 313
  issue: 3
  year: 1998
  ident: 2187_CR9
  publication-title: Immunol Res
  doi: 10.1007/BF02786454
– volume: 73
  start-page: 236
  issue: 3
  year: 2012
  ident: 2187_CR56
  publication-title: Gynecol Obstet Invest
  doi: 10.1159/000334175
– volume: 128
  start-page: 723
  issue: 11
  year: 2020
  ident: 2187_CR8
  publication-title: Exp Clin Endocrinol Diabetes
  doi: 10.1055/a-0992-9114
– volume: 160
  start-page: 469
  issue: 3
  year: 2009
  ident: 2187_CR55
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-08-0725
– volume: 10
  start-page: 879
  year: 2019
  ident: 2187_CR4
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/fendo.2019.00879
– volume: 2018
  start-page: 9591509
  year: 2018
  ident: 2187_CR60
  publication-title: Int J Inflamm
  doi: 10.1155/2018/9591509
– ident: 2187_CR33
– volume: 30
  start-page: 58
  issue: 1
  year: 2017
  ident: 2187_CR22
  publication-title: J Pediatr Adolesc Gynecol
  doi: 10.1016/j.jpag.2016.06.010
– volume: 3
  start-page: 1101
  issue: 6
  year: 2008
  ident: 2187_CR32
  publication-title: Nat Protoc
  doi: 10.1038/nprot.2008.73
– volume: 81
  start-page: 1535
  issue: 4
  year: 2001
  ident: 2187_CR47
  publication-title: Physiol Rev
  doi: 10.1152/physrev.2001.81.4.1535
– volume: 157
  start-page: 53
  issue: 1
  year: 2011
  ident: 2187_CR36
  publication-title: Eur J Obstet Gynecol Reprod Biol
  doi: 10.1016/j.ejogrb.2011.03.015
– volume: 11
  issue: 10
  year: 2016
  ident: 2187_CR14
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0164021
– volume: 39
  start-page: 75
  year: 2005
  ident: 2187_CR31
  publication-title: Biotechniques
  doi: 10.2144/05391RV01
– volume: 352
  start-page: 1463
  issue: 14
  year: 2005
  ident: 2187_CR41
  publication-title: Acne N Engl J Med
  doi: 10.1056/NEJMcp033487
– volume: 5
  start-page: 305
  issue: 6
  year: 2009
  ident: 2187_CR63
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/nrendo.2009.62
– volume: 36
  start-page: 278
  issue: 3
  year: 2021
  ident: 2187_CR25
  publication-title: Indian J Clin Biochem
  doi: 10.1007/s12291-020-00901-w
– volume: 4
  start-page: 77
  issue: 1
  year: 2006
  ident: 2187_CR51
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2005.01690.x
– volume: 60
  start-page: 1
  issue: 1
  year: 2012
  ident: 2187_CR67
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2012.06.018
– start-page: 205
  volume-title: Managing the PCOS-related symptoms of hirsutism, acne, and female pattern hair loss. Polycystic ovary syndrome
  year: 2022
  ident: 2187_CR40
– volume: 94
  start-page: 31
  issue: 1
  year: 2001
  ident: 2187_CR45
  publication-title: QJM
  doi: 10.1093/qjmed/94.1.31
– volume: 73
  start-page: 22
  year: 2017
  ident: 2187_CR21
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2017.05.001
– volume: 95
  start-page: 295
  issue: 1
  year: 2011
  ident: 2187_CR37
  publication-title: Fertil Steril
  doi: 10.1016/j.fertnstert.2010.08.030
– volume: 219
  start-page: 101
  issue: 2
  year: 2013
  ident: 2187_CR59
  publication-title: J Endocrinol
  doi: 10.1530/JOE-13-0277
– volume: 21
  start-page: 1440
  year: 1961
  ident: 2187_CR27
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem-21-11-1440
– volume: 116
  start-page: 585
  issue: Pt 4
  year: 2003
  ident: 2187_CR48
  publication-title: J Cell Sci
  doi: 10.1242/jcs.00247
– volume: 147
  start-page: 14
  year: 2018
  ident: 2187_CR34
  publication-title: J Microbiol Methods
  doi: 10.1016/j.mimet.2018.02.011
– volume: 15
  start-page: 785
  issue: 4
  year: 2000
  ident: 2187_CR46
  publication-title: Hum Reprod
  doi: 10.1093/humrep/15.4.785
– volume: 26
  start-page: 1478
  issue: 6
  year: 2011
  ident: 2187_CR57
  publication-title: Hum Reprod
  doi: 10.1093/humrep/der096
– volume: 11
  start-page: 1
  issue: 1
  year: 2021
  ident: 2187_CR69
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-84586-y
– volume: 10
  start-page: 699
  year: 2019
  ident: 2187_CR39
  publication-title: Front Endocrinol
  doi: 10.3389/fendo.2019.00699
– volume: 4
  start-page: 813
  issue: 11
  year: 2006
  ident: 2187_CR35
  publication-title: Clin Adv Hematol Oncol
– volume: 117
  start-page: 166
  issue: 2
  year: 2015
  ident: 2187_CR12
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.117.306666
– volume: 53
  start-page: 157
  issue: 2
  year: 2006
  ident: 2187_CR49
  publication-title: Endocr J
  doi: 10.1507/endocrj.53.157
– volume: 185
  start-page: 102
  year: 2020
  ident: 2187_CR18
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2019.11.019
– volume: 13
  start-page: 261
  issue: 4
  year: 2020
  ident: 2187_CR1
  publication-title: J Hum Reprod Sci
  doi: 10.4103/jhrs.JHRS_95_18
– volume: 73
  start-page: 1423
  issue: 7
  year: 1993
  ident: 2187_CR10
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90367-Y
– volume: 11
  start-page: 212
  issue: 6
  year: 2000
  ident: 2187_CR65
  publication-title: Trends Endocrinol Metab
  doi: 10.1016/S1043-2760(00)00272-1
– volume: 57
  start-page: 1501
  issue: 6
  year: 2008
  ident: 2187_CR58
  publication-title: Diabetes
  doi: 10.2337/db08-0127
– volume: 6
  start-page: 17714
  year: 2016
  ident: 2187_CR17
  publication-title: Sci Rep
  doi: 10.1038/srep17714
– volume: 240
  start-page: 36
  year: 2019
  ident: 2187_CR5
  publication-title: Eur J Obstet Gynecol Reprod Biol
  doi: 10.1016/j.ejogrb.2019.06.018
– volume: 13
  start-page: 1957
  issue: 3
  year: 2019
  ident: 2187_CR38
  publication-title: Diabetes Metab Syndr
  doi: 10.1016/j.dsx.2019.04.032
– volume: 12
  start-page: 97
  issue: 1
  year: 2019
  ident: 2187_CR6
  publication-title: J Ovarian Res
  doi: 10.1186/s13048-019-0566-5
– volume: 46
  start-page: 116
  issue: 1
  year: 2021
  ident: 2187_CR68
  publication-title: Miner Endocrinol
– volume: 122
  start-page: 223
  issue: 4
  year: 2016
  ident: 2187_CR7
  publication-title: Arch Physiol Biochem
  doi: 10.1080/13813455.2016.1190760
– volume: 148
  start-page: S151
  issue: Suppl
  year: 2018
  ident: 2187_CR23
  publication-title: Indian J Med Res
– volume: 20
  start-page: 1695
  issue: 16
  year: 2019
  ident: 2187_CR16
  publication-title: Curr Drug Targets
  doi: 10.2174/1389450120666190715102510
– volume: 149
  start-page: 231
  issue: 2
  year: 2020
  ident: 2187_CR2
  publication-title: Int J Gynaecol Obstet
  doi: 10.1002/ijgo.13125
– volume: 85
  start-page: 2402
  issue: 7
  year: 2000
  ident: 2187_CR29
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem.85.7.6661
– volume: 25
  start-page: 779
  issue: 3
  year: 2010
  ident: 2187_CR54
  publication-title: Hum Reprod
  doi: 10.1093/humrep/dep459
– volume: 27
  start-page: S53
  issue: Suppl 3
  year: 2003
  ident: 2187_CR64
  publication-title: Int J Obes Relat Metab Disord
  doi: 10.1038/sj.ijo.0802502
– volume: 265
  start-page: 403
  year: 2018
  ident: 2187_CR28
  publication-title: Sens Actuators B Chem
  doi: 10.1016/j.snb.2018.03.053
– volume: 38
  start-page: 54
  issue: 1
  year: 2011
  ident: 2187_CR61
  publication-title: Clin Exp Obstet Gynecol
– volume: 28
  start-page: 412
  issue: 7
  year: 1985
  ident: 2187_CR30
  publication-title: Diabetologia
  doi: 10.1007/BF00280883
– volume: 22
  start-page: 317
  issue: 2
  year: 2007
  ident: 2187_CR44
  publication-title: Hum Reprod
  doi: 10.1093/humrep/del407
SSID ssj0017857
Score 2.3440866
Snippet Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and...
Abstract Background Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss,...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 68
SubjectTerms Body Mass Index
Chemokine CCL2 - genetics
Contraceptives, Oral - therapeutic use
Female
Gene Expression
Humans
Inflammation
Insulin
Intercellular Adhesion Molecule-1 - genetics
Intercellular Adhesion Molecule-1 - therapeutic use
Leukocytes, Mononuclear - metabolism
Monocyte chemoattractant protein-1
Oral contraceptive pill
Plasminogen activator inhabitor-1
Plasminogen Activator Inhibitor 1 - genetics
Plasminogen Activator Inhibitor 1 - therapeutic use
Polycystic ovary syndrome
Polycystic Ovary Syndrome - drug therapy
Polycystic Ovary Syndrome - genetics
RNA, Messenger - metabolism
RNA, Messenger - therapeutic use
Tumor Necrosis Factor-alpha
Tumor necrosis factor-α
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NitswEFbLngql9L_pH1PoIUtrNrJlyz6moWG3kE2gu7A3I0tyY0jskDiheay-SJ-pM7IdNqW0l54C8Xg8Ft9YI2nmG8beS8UDI0zgSWGlJ4zIvSzWvkdkcLGOI-27-orJZXR-Lb7chDe3Wn1RTlhDD9wM3JkaEAF7KFUeDkSW5BjgcK2FCHMV-LEx9PXFOa9bTLXnBzIOZVciE0dnG9ptoUpkOrPk6Fbh0TTk2Pr_FGL-nil5a-oZP2QP2pgRho2tj9hdWz5m95sNN2jqiJ7cSaZ4J7jMc-VSVXYWVsViAf3paHYKh4RycOfjG8DADxA8Fuz3Nhe2hCoHoo9wu_mUngrKzK27smy66FqPQ_9iNJx4_PQj1NtltYbS0isWG2ha93g_f0D_6nKMvyiCIK_0vraA2FhWqibjqG8xOH6IoiR9k9EM1YEqDawwll8WZYWGAVVc7GhLAG2aF1lBulF6Nrwg6aKEVbXY6z3xTEO1U-s9dOwLKDSafj0Fxy4BXZY91BWY9fabVyoaGxJpJJ6y6_Hnq9G51_aF8LSI4trTg9xoP1RB7uN6zFdaZ3agEusbleSDQc65Ih65POCZlpGIFC7prAqVMBmGqwiCZ-ykrEr7goHlkZSBzDVqw9BGJHkYRomJE8OlibjqMd7BJNUtaTr17likbvEUR2kDrRS1pg5aadhjHw73rBrKkL9KfyL0HSSJ7tv9gU6Qtk6Q_ssJeuxdh90UPw-EElXaartJfYnxPXH4JD32vMHy4VFBJGk4_B6TRyg_suX4SlnMHQU5RrX44Ojl_zD-FbvnN57p8fA1O6nXW_sGI706e-uc-hc_xlM-
  priority: 102
  providerName: Directory of Open Access Journals
Title Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women
URI https://www.ncbi.nlm.nih.gov/pubmed/36793022
https://www.proquest.com/docview/2777405359
https://pubmed.ncbi.nlm.nih.gov/PMC9933286
https://doaj.org/article/a0700457af504b9f8001cc445fa328dd
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ta9swENb6AqMwxt6XvYQb7EPL5s3ym-wPY7ShpR2kDV0LZV-MLMmtIbGzxCnNz9of2W_anRxny-j2JYb4dJbt56w76fQcY2-F5L4OtO-IwAgn0EHuZLHyHCKDi1UcKc_ur-gfR4fnwZeL8GKNteWOFg9wemtoR_WkzifDDzff55_R4D9Zg4-jj1OaS6F9xrQiydFownW2iSOToIoG_eD3qoKIQ9FunLm13Ra760eIWNfzVsYpS-d_mw_6dyrlH2PTwQN2f-FUwm6DgodszZSP2L1mRg6ajUaP7yQn2BJsarq0uSzXBsbFcAjbJ73BDiwzzsEuoE8BPUNAdBkwN4tk2RKqHIhfwk73U_4qSH1l7JlRU2bXOBy2j3q7fYfvvId6NqomUBq6xWIKTW0f5-cP2D47PsAjiqAVVGpeG0DwjCpZU-eosDFYAomiJH393gDVgSw1jNHZHxVlhR0D2pJxTXMG2KerIitIN0oPdo9IuihhXA3nak5E1FBdy8kcWnoGFOqdfN0BSz8BbRo-1BXoyezSKSU9GxJpJJ6w84P9s96hsygc4aggimtHublWXij93MOAzZNKZcaVifG0THLXzTmXRDSX-zxTIgoiiTGfkaEMdMbp5ftP2UZZleY5A8MjIXyRK9SGvk-Q5GEYJTpONBc64rLDeAuTVC1Y1am4xzC10VUcpQ3KUtSaWpSlYYe9W7YZN5wi_5XeI_QtJYkP3P5RTS7TxecllS6VKQiFzEM3yJIcwwCuVBCEufS9WOsOe9NiN8XvB6FElqaaTVNPYABAJD9Jhz1rsLy8VGsLHSZWUL7Sl9UzZXFlOcrR7cULRy_-qfMl2_Iay3N4-Ipt1JOZeY3-XZ112bq4EF22ubd_PDjt2lmSrjVk_D3d-_YLyQZSqw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+contraceptive+pill+%28OCP%29+treatment+alters+the+gene+expression+of+intercellular+adhesion+molecule-1+%28ICAM-1%29%2C+tumor+necrosis+factor-%CE%B1+%28TNF-%CE%B1%29%2C+monocyte+chemoattractant+protein-1+%28MCP-1%29+and+plasminogen+activator+inhibitor-1+%28PAI-1%29+in+polycystic+ovary+syndrome+%28PCOS%29+women+compared+to+drug-naive+PCOS+women&rft.jtitle=BMC+women%27s+health&rft.au=Yousuf%2C+Syed+Douhath&rft.au=Ganie%2C+Mohammad+Ashraf&rft.au=Urwat%2C+Uneeb&rft.au=Andrabi%2C+Syed+Mudasir&rft.date=2023-02-15&rft.eissn=1472-6874&rft.volume=23&rft.issue=1&rft.spage=68&rft_id=info:doi/10.1186%2Fs12905-023-02187-5&rft_id=info%3Apmid%2F36793022&rft.externalDocID=36793022
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6874&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6874&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6874&client=summon